PF-06671008 / Pfizer - LARVOL DELTA

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. (PubMed, Front Immunol) - P1 | "Cytokine peak concentrations and CRS grade appeared to positively correlate with C. Although the study was terminated due to limited antitumor activity, it provides important insights into understanding and managing immune-related adverse events resulting from this class of molecules. URL: https://clinicaltrials.gov/ct2/show/NCT02659631, ClinicalTrials.gov Identifier: NCT02659631."

Journal • P1 data • Inflammation • Oncology • Renal Disease • Solid Tumor • CDH3

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART. (PubMed, AAPS J) - "The predicted terminal half-life of PF-06671008 in the clinic was approximately 1 day, and P-cadherin expression and number of T cells in the tumor were shown to be sensitive parameters impacting clinical efficacy. A translational QSP model is presented for CD3 bispecific molecules, which integrates in silico, in vitro and in vivo data in a mechanistic framework, to quantify and predict efficacy across species."

Journal

PF-06671008 Dose Escalation Study in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=28; Terminated; Sponsor: Pfizer; Active, not recruiting ➔ Terminated

Clinical • Trial termination